ArticleFrontiers in aging neuroscience2024

Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD).

Andreas W Wolff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.